(12 intermediate revisions by 4 users not shown) | |||
Line 11: | Line 11: | ||
padding: 0; | padding: 0; | ||
} | } | ||
+ | |||
+ | Css-> | ||
+ | |||
+ | #ImpressumSponsoren{ | ||
+ | bottom:0px; | ||
+ | margin-left: 25em; | ||
+ | margin-bottom: 5em; | ||
+ | margin-right: 10em; | ||
+ | text-align: right; | ||
+ | } | ||
#BigImageLab{ | #BigImageLab{ | ||
Line 126: | Line 136: | ||
grid-template-rows: auto; | grid-template-rows: auto; | ||
margin-bottom: 5em; | margin-bottom: 5em; | ||
− | margin-top: - | + | margin-top: -25em; |
} | } | ||
Line 224: | Line 234: | ||
<a href="https://2017.igem.org/Team:Tuebingen/Inspiration"style="margin-right:1.5em;">Inspiration</a> | <a href="https://2017.igem.org/Team:Tuebingen/Inspiration"style="margin-right:1.5em;">Inspiration</a> | ||
<a href="https://2017.igem.org/Team:Tuebingen/Demonstrate"style="margin-right:1.5em;">Results</a> | <a href="https://2017.igem.org/Team:Tuebingen/Demonstrate"style="margin-right:1.5em;">Results</a> | ||
− | <a href="https://2017.igem.org/Team:Tuebingen/HP | + | <a href="https://2017.igem.org/Team:Tuebingen/HP"style="margin-right:1.5em;">Human Practice</a> |
<a href="https://2017.igem.org/Team:Tuebingen/Lab"style="margin-right:1.5em;">Lab</a> | <a href="https://2017.igem.org/Team:Tuebingen/Lab"style="margin-right:1.5em;">Lab</a> | ||
<a href="https://2017.igem.org/Team:Tuebingen/Attributions"style="margin-right:1.5em;">Attributions</a> | <a href="https://2017.igem.org/Team:Tuebingen/Attributions"style="margin-right:1.5em;">Attributions</a> | ||
</div> | </div> | ||
− | + | <div style="max-width:100%;"> | |
− | + | <img src="https://static.igem.org/mediawiki/2017/8/8c/T--Tuebingen--LabTitle.jpg" alt="InterLabBild" id="BigImageLab"> | |
+ | |||
+ | <div style="position: absolute; text-align:right; | ||
+ | margin-bottom: 10%; | ||
+ | margin-left: 60%; | ||
+ | margin-top:-4em; | ||
+ | font-size: 3em;color:white;font-weight:light;letter-spacing: 3px;"> basic parts | ||
+ | </div> </div> | ||
Line 257: | Line 274: | ||
− | <p | + | <p><a href="http://parts.igem.org/Part:BBa_K2372004"id="BBa_K2372004" class="anchor">BBa_K2372004</a> </p> |
<p> SHV-1 is a β-lactamase that mediates resistance against ꞵ-lactams </p> | <p> SHV-1 is a β-lactamase that mediates resistance against ꞵ-lactams </p> | ||
Line 264: | Line 281: | ||
− | <p | + | <p> <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2372000"id="BBa_K2372000" class="anchor">BBa_K2372000</a> </p> |
<p> CouL is a amide synthetase that catalyzes the bonding of the amide bonds in aminocoumarin antibiotics | <p> CouL is a amide synthetase that catalyzes the bonding of the amide bonds in aminocoumarin antibiotics | ||
Line 272: | Line 289: | ||
− | <p | + | <p> <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2372001"id="BBa_K2372001" class="anchor">BBa_K2372001</a> </p> |
Line 280: | Line 297: | ||
− | <p | + | <p> <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2372002"id="BBa_K2372002" class="anchor">BBa_K2372002</a> </strong> </p> |
<p> β-lactam synthetase (BLS) catalyzes the formation of the β-lactam ring of clavulanic acid | <p> β-lactam synthetase (BLS) catalyzes the formation of the β-lactam ring of clavulanic acid | ||
Line 287: | Line 304: | ||
− | <p | + | <p> <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2372003"id="BBa_K2372003" class="anchor">BBa_K2372003</a> </strong> </p> |
Line 294: | Line 311: | ||
− | <p | + | <p> <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2372005"id="BBa_K2372005" class="anchor">BBa_K2372005</a> </p> |
<p> Gyrase B (GyrB)is a type II topoisomerase | <p> Gyrase B (GyrB)is a type II topoisomerase | ||
Line 300: | Line 317: | ||
− | <p> | + | <p> <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2372006"id="BBa_K2372006" class="anchor">BBa_K2372006</a> </p> |
<p> Gyrase B (GyrB)is a type II topoisomerase | <p> Gyrase B (GyrB)is a type II topoisomerase | ||
Line 310: | Line 327: | ||
− | + | <div id="ImpressumSponsoren"> | |
+ | <img src="https://static.igem.org/mediawiki/2017/5/58/T%C3%BCbingen_Qiagen-Logo.jpeg" id="Quiagen" width=70px> <img src="https://static.igem.org/mediawiki/2017/1/1c/T%C3%BCbingen_Roth-Logo.jpeg" id="Roth" width=70px> <img src="https://static.igem.org/mediawiki/2017/d/d8/TuebingenZymoLogo.jpeg" width=150px> <img src="https://static.igem.org/mediawiki/2017/5/5b/T%C3%BCbingen_Eurofins-Logo.png" id="eurofins" width=150px> <img src="https://static.igem.org/mediawiki/2017/e/e4/GATCTuebingen.png" id="GATC" width=150px> <img src="https://static.igem.org/mediawiki/2017/4/49/T%C3%BCbingen_NEB-Logo.jpeg" id="BioLabs" width=150px><br><img src="https://static.igem.org/mediawiki/2017/7/7c/T%C3%BCbingen_Greiner-Logo.jpeg" id="Greiner" width=150px> <img src="https://static.igem.org/mediawiki/2017/b/bf/T%C3%BCbingen_Agilent-Logo.jpeg" id="Agilent" width=150px> <img src="https://static.igem.org/mediawiki/2017/0/01/T%C3%BCbingen_abcr-Logo.png" id="abcr" width=150px> <img src="https://static.igem.org/mediawiki/2017/5/59/MicrosynthTuebingen.png" width=150px> <img src="https://static.igem.org/mediawiki/2017/8/8b/Eppendorftuebingen.png" width=150px> | ||
+ | <div> <p> © iGEM Team Tuebingen 2017</p></div> | ||
</div> | </div> | ||
+ | |||
</body> | </body> | ||
</html> | </html> |
Latest revision as of 12:38, 12 December 2017
basic parts
Basic Parts
SHV-1 is a β-lactamase that mediates resistance against ꞵ-lactams
CouL is a amide synthetase that catalyzes the bonding of the amide bonds in aminocoumarin antibiotics
CloL is a amide synthetase that catalyzes the bonding of the amide bonds in aminocoumarin antibiotics
β-lactam synthetase (BLS) catalyzes the formation of the β-lactam ring of clavulanic acid
The BLS mutant is a rationally designed mutant of the β-lactam synthetase
Gyrase B (GyrB)is a type II topoisomerase
Gyrase B (GyrB)is a type II topoisomerase
© iGEM Team Tuebingen 2017